Milestone Scientific (MLSS) 10-Q 13 Aug 21 2021 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2021	Aug. 13, 2021
Document Information [Line Items]
Entity Central Index Key	0000855683
Entity Registrant Name	MILESTONE SCIENTIFIC INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	001-14053
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-3545623
Entity Address, Address Line One	425 Eagle Rock Avenue Suite 403
Entity Address, City or Town	Roseland
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07068
City Area Code	973
Local Phone Number	535-2717
Title of 12(b) Security	Common Stock, par value $.001 per share
Security Exchange Name	NYSEAMER
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Trading Symbol	MLSS
Entity Common Stock, Shares Outstanding		67,166,428

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 15,977,330	$ 14,223,917
Accounts receivable, net	812,341	1,080,656
Accounts receivable, related party net	0	0
Prepaid expenses and other current assets	442,295	415,915
Inventories, net	1,479,391	2,420,179
Advances on contracts	1,393,817	414,202
Total current assets	20,105,174	18,554,869
Furniture, fixtures and equipment, net	30,749	30,729
Intangibles, net	306,544	329,249
Right of use assets	593,049	632,453
Other assets	24,150	24,150
Total assets	21,059,666	19,571,450
Current liabilities:
Accounts payable	582,684	482,972
Accounts payable, related party	201,887	385,138
Accrued expenses and other payables	1,390,560	824,454
Accrued expenses, related party	352,209	586,734
Current portion of finance leases liabilities	8,162	7,796
Current portion of operating lease right-of-use liabilities	76,008	72,031
Deferred profit, related party	337,145	242,589
Note payable	0	276,180
Total current liabilities	2,948,655	2,877,894
Finance lease liabilities	24,433	28,607
Operating lease liabilities	518,408	557,981
Total liabilities	3,491,496	3,464,482
Commitments and contingencies
Stockholders’ equity
Common stock, par value $.001; authorized 100,000,000 shares; 67,055,869 shares issued and 67,022,536 shares outstanding as of June 30, 2021; 64,171,435 shares issued and 64,138,102 shares outstanding as of December 31, 2020;	67,055	64,171
Additional paid in capital	123,075,664	117,934,696
Accumulated deficit	(104,539,294)	(100,885,957)
Treasury stock, at cost, 33,333 shares	(911,516)	(911,516)
Total Milestone Scientific Inc. stockholders' equity	17,691,909	16,201,394
Noncontrolling interest	(123,739)	(94,426)
Total stockholders’ equity	17,568,170	16,106,968
Total liabilities and stockholders’ equity	$ 21,059,666	$ 19,571,450

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	67,055,869	64,171,435
Common stock, shares outstanding (in shares)	67,022,536	64,138,102
Treasury stock, at cost, shares (in shares)	33,333	33,333

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Product sales, net	$ 2,425,738	$ 167,674	$ 5,350,445	$ 1,979,060
Cost of products sold	1,056,384	55,626	2,178,797	615,326
Gross profit	1,369,354	112,048	3,171,648	1,363,734
Selling, general and administrative expenses	4,011,672	3,155,630	6,760,969	5,875,123
Research and development expenses	14,834	108,170	35,760	215,650
Depreciation and amortization expense	215,420	21,138	231,864	54,457
Total operating expenses	4,241,926	3,284,938	7,028,593	6,145,230
Loss from operations	(2,872,572)	(3,172,890)	(3,856,945)	(4,781,496)
Interest expense	(4,461)	(4,062)	(6,996)	(8,159)
Gain on debt extinguishment-PPP	276,180	0	276,180	0
Loss before provision for income taxes and net of equity investments	(2,600,853)	(3,176,952)	(3,587,761)	(4,789,655)
Provision for income taxes	(83)	(1,250)	(333)	(1,500)
Loss before equity in net earnings (losses) of equity investments	(2,600,936)	(3,178,202)	(3,588,094)	(4,791,155)
Loss from China Joint Venture	(95,857)	0	(94,556)	0
Net loss	(2,696,793)	(3,178,202)	(3,682,650)	(4,791,155)
Net loss attributable to noncontrolling interests	(16,325)	(11,738)	(29,313)	(24,476)
Net loss attributable to Milestone Scientific Inc.	$ (2,680,468)	$ (3,166,464)	$ (3,653,337)	$ (4,766,679)
Net loss per share applicable to common stockholders—
Basic (in dollars per share)	$ (0.04)	$ (0.06)	$ (0.05)	$ (0.09)
Diluted (in dollars per share)	$ (0.04)	$ (0.06)	$ (0.05)	$ (0.09)
Weighted average shares outstanding and to be issued—
Basic (in shares)	69,220,795	56,694,793	68,286,033	51,728,806
Diluted (in shares)	69,220,795	56,694,793	68,286,033	51,728,806

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Consultant [Member]Common Stock [Member]	Consultant [Member]Additional Paid-in Capital [Member]	Consultant [Member]	Board of Directors [Member]Common Stock [Member]	Board of Directors [Member]Additional Paid-in Capital [Member]	Board of Directors [Member]	June 30, 2020 Public Offering [Member]Common Stock [Member]	June 30, 2020 Public Offering [Member]Additional Paid-in Capital [Member]	June 30, 2020 Public Offering [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Treasury Stock [Member]	Total
Balance (in shares) at Dec. 31, 2019										49,410,176
Balance at Dec. 31, 2019										$ 49,410	$ 96,082,324	$ (93,524,297)	$ (67,274)	$ (911,516)	$ 1,628,647
Stock based compensation											30,715				30,715
Common stock issued to employee for compensation expensed in prior periods (in shares)										22,633
Common stock issued to employee for compensation expensed in prior periods										$ 23	14,989				15,012
Common stock to issued for services		$ 25,000	$ 25,000
Common stock to be issued to employees for bonuses											171,046				171,046
Common stock issued for warrants exercised (in shares)										460,725
Common stock issued for warrants exercised										$ 460	229,902				230,362
Net loss												(1,600,215)	(12,738)		(1,612,953)
Common stock issued for warrants exercised										$ 460	229,902				230,362
Balance (in shares) at Mar. 31, 2020										49,893,534
Balance at Mar. 31, 2020										$ 49,893	96,553,976	(95,124,512)	(80,012)	(911,516)	487,829
Balance (in shares) at Dec. 31, 2019										49,410,176
Balance at Dec. 31, 2019										$ 49,410	96,082,324	(93,524,297)	(67,274)	(911,516)	1,628,647
Net loss															(4,791,155)
Balance (in shares) at Jun. 30, 2020										63,236,165
Balance at Jun. 30, 2020										$ 63,236	116,199,595	(95,148,899)	(55,625)	(911,516)	16,968,589
Balance (in shares) at Mar. 31, 2020										49,893,534
Balance at Mar. 31, 2020										$ 49,893	96,553,976	(95,124,512)	(80,012)	(911,516)	487,829
Stock based compensation											23,946				23,946
Common stock issued to employee for compensation expensed in prior periods (in shares)										11,450
Common stock issued to employee for compensation expensed in prior periods										$ 11	14,989				15,000
Common stock to issued for services (in shares)	278,581			39,233
Common stock to issued for services	$ 279	$ 381,520	381,799	$ 39	$ 53,967	$ 54,006
Common stock to be issued to employees for bonuses											462,504				462,504
Common stock issued for warrants exercised (in shares)										620,750
Common stock issued for warrants exercised										$ 621	718,029				718,650
Net loss												(3,166,464)	(11,738)		(3,178,202)
Common stock issued for warrants exercised										$ 621	718,029				718,650
Common stock issued to employees for bonuses (in shares)										202,617
Common stock issued to employees for bonuses										$ 203	(203)				0
Common stock issued in public offering (in shares)							6,770,000			5,420,000
Common stock issued in public offering							$ 6,770	$ 13,369,845	$ 13,376,615	$ 5,420	4,621,022				4,626,442
Acquired controlling interest in Milestone Advanced Cosmetic Systems												(24,387)	24,387
Balance (in shares) at Jun. 30, 2020										63,236,165
Balance at Jun. 30, 2020										$ 63,236	116,199,595	(95,148,899)	(55,625)	(911,516)	16,968,589
Balance (in shares) at Dec. 31, 2020										64,171,435
Balance at Dec. 31, 2020										$ 64,171	117,934,696	(100,885,957)	(94,426)	(911,516)	16,106,968
Stock based compensation											113,507				113,507
Common stock issued to employee for compensation expensed in prior periods (in shares)										7,075
Common stock issued to employee for compensation expensed in prior periods										$ 7					7
Common stock to be issued for payment of consulting services expensed in prior periods (in shares)	40,010
Common stock to be issued for payment of consulting services expensed in prior periods	$ 40		$ 40
Common stock to issued for services (in shares)				18,879
Common stock to issued for services				$ 18		18
Common stock issued to employee for stock options exercised (in shares)										435,558
Common stock issued to employee for stock options exercised										$ 436	689,754				690,190
Common stock to be issued to employees for bonuses											100,000				100,000
Common stock issued for warrants exercised (in shares)										1,918,925
Common stock issued for warrants exercised										$ 1,919	3,010,297				3,012,216
Net loss												(972,869)	(12,988)		(985,857)
Common stock issued for warrants exercised										$ 1,919	3,010,297				3,012,216
Balance (in shares) at Mar. 31, 2021										66,591,882
Balance at Mar. 31, 2021										$ 66,591	121,848,254	(101,858,826)	(107,414)	(911,516)	19,037,089
Balance (in shares) at Dec. 31, 2020										64,171,435
Balance at Dec. 31, 2020										$ 64,171	117,934,696	(100,885,957)	(94,426)	(911,516)	16,106,968
Net loss															(3,682,650)
Balance (in shares) at Jun. 30, 2021										67,055,869
Balance at Jun. 30, 2021										$ 67,055	123,075,664	(104,539,294)	(123,739)	(911,516)	17,568,170
Balance (in shares) at Mar. 31, 2021										66,591,882
Balance at Mar. 31, 2021										$ 66,591	121,848,254	(101,858,826)	(107,414)	(911,516)	19,037,089
Stock based compensation											193,824				193,824
Common stock issued to employee for compensation expensed in prior periods (in shares)										4,202
Common stock issued to employee for compensation expensed in prior periods										$ 4	14,996				15,000
Common stock to be issued for payment of consulting services expensed in prior periods (in shares)										96,018
Common stock to be issued for payment of consulting services expensed in prior periods										$ 94	262,589				262,683
Common stock to issued for services (in shares)				277,767
Common stock to issued for services				$ 280	$ 617,887	$ 618,167
Common stock issued for warrants exercised (in shares)										86,000
Common stock issued for warrants exercised										$ 86	138,114				138,200
Net loss												(2,680,468)	(16,325)		(2,696,793)
Common stock issued for warrants exercised										$ 86	138,114				138,200
Balance (in shares) at Jun. 30, 2021										67,055,869
Balance at Jun. 30, 2021										$ 67,055	$ 123,075,664	$ (104,539,294)	$ (123,739)	$ (911,516)	$ 17,568,170

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Net loss	$ (3,682,650)	$ (4,791,155)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	13,055	31,851
Amortization of patents	22,705	26,506
Stock compensation	307,331	58,219
Employees paid in stock	748,171	714,005
Expense paid in stock	262,713	406,800
Loss on China joint venture	94,556	0
Non-cash operating lease expense	3,808	28,901
Gain on debt extinguishment-PPP	(276,180)	0
Changes in operating assets and liabilities:
Decrease in accounts receivable	268,315	1,603,379
Increase in accounts receivable, related party	0	0
Decrease in other assets	0	11,755
(Increase) decrease in inventories	940,788	(231,944)
Decrease in advances on contracts	(979,615)	(131,518)
Decrease in prepaid expenses and other current assets	(26,380)	50,162
Increase (Decrease) in accounts payable	99,713	(917,898)
(Decrease) increase in accounts payable, related party	(183,251)	(839,359)
Decrease in accrued expenses	551,136	272,953
Increase in accrued expenses, related party	(234,525)	(404,161)
Net cash used in operating activities	(2,070,310)	(4,111,504)
Cash flows from investing activities:
Purchase of property and equipment	(13,075)	(15,499)
Net cash used in investing activities	(13,075)	(15,499)
Cash flows from financing activities:
Proceeds from exercise of warrants	3,150,416	949,012
Payments finance lease obligations	(3,808)	(3,200)
Net proceeds from employee options exercised	690,190	0
Net proceeds from note payable	0	272,099
Net proceeds from Public Placement Offering	0	18,003,037
Net cash provided by financing activities	3,836,798	19,220,948
Net increase in cash and cash equivalents	1,753,413	15,093,945
Cash and cash equivalents at beginning of period	14,223,917	1,516,272
Cash and cash equivalents at end of period	15,977,330	16,610,217
Supplemental non-cash disclosure of cash flow information:
Initial recognition of operating lease-right of use assets	0	(706,071)
Initial recognition of operating lease right to used liabilities	$ 0	$ 706,071

Note 1 - Organization and Busin

Note 1 - Organization and Business	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1 All references in this report to “Milestone Scientific,” “us,” “our,” “we,” the “Company” or “Milestone” refer to Milestone Scientific Inc., and its consolidated subsidiaries, Wand Dental, Inc., Milestone Advanced Cosmetic Systems, Inc., Milestone Medical, Inc. and Milestone Education LLC (all described below), unless the context otherwise indicates. Milestone Scientific is the owner of the following registered U.S. trademarks: C ompuDent ; CompuMed ; CompuFlo ; DPS Dynamic Pressure Sensing technology ; Milestone Scientific ; the Milestone logo ; SafetyWand ; STA Single Tooth Anesthesia System ; and The Wand . Milestone Scientific was incorporated in the State of Delaware in August 1989. The Wand CompuDent , STA Single Tooth Anesthesia System CompuMed . CompuDent CompuMed June 2017, 510 CompuFlo In December 2016, 510 not 510 510 2019, 510 not 2019 2020. June 30,2021, not In April June 2020, two 9 June 30,2021, December 31, 2020.

Note 2 - Liquidity and Uncertai

Note 2 - Liquidity and Uncertainties	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE 2 AND UNCERTAINTIES The Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one June 30, 2021, three six June 30, 2021. In April June 2020, 9 June 30,2021, December 31, 2020. The coronavirus (COVID- 19 third 19, three six June 30, 2020, 19 2021. In addition to our employees, we rely on (i) distributors, agents, and third third third may In addition, it is uncertain as to what effect the continuing spread of COVID- 19

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 3 1. The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), Milestone Advanced Cosmetic (majority owned), and Milestone Medical (majority owned). All significant, intra-entity transactions and balances have been eliminated in consolidation. 2. The unaudited condensed consolidated financial statements of Milestone Scientific have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information with the instructions for Form 10 8 X. not not may December 31, 2020, 10 3. Certain reclassification has been made to the 2020 2021 no 4. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the allowance for doubtful accounts, inventory valuation, cash flow assumptions regarding evaluations for impairment of long-lived assets and going concern considerations, and valuation allowances on deferred tax assets. Actual results could differ from those estimates. 5. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To perform revenue recognition for customer arrangements the Company performs the following five i. identification of the promised goods or services in the contract; ii. determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; iii. measurement of the transaction price, including the constraint on variable consideration; iv. allocation of the transaction price to the performance obligations based on estimated standalone selling prices; and selling prices; and v. recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606, The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products through a global distribution network and that includes both exclusive and non-exclusive distribution agreements with related and third Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon date of shipment. For certain arrangements where the shipping terms are freight-on-board (FOB) shipping, revenue is recognized upon delivery. The Company has no Sales Returns The Company records allowances for product returns as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including the customers’ return rights and the Company’s historical experience with returns and the amount of product in the distribution channel not may Financing and Payment Our payment terms differ by geography and customer, but payment is generally required within 90 Disaggregation of Revenue We operate in two 11 six June 30, 2021 6. A variable interest entity ("VIE") is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE. Because Milestone Scientific has a variable interest in Milestone China it considered the guidance in ASC 810, ● Power Criterion: The power to direct the activities that most significantly impact the entity’s economic performance; and ● Losses/Benefits Criterion: The obligation to absorb losses that could potentially be significant or the right to receive benefits that could potentially be significant to the VIE. Milestone Scientific does not not not 810. 6. 7. Milestone Scientific considers all highly liquid investments purchased with an original maturity of three June 30, 2021, December 31, 2020 may 8. Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the inability of its customers to make payments on amounts billed. Most credit sales are due within 90 not June 30, 2021 December 31, 2020 9. Inventories principally consist of finished goods and component parts stated at the lower of cost ( first first not June 30,2021, December 31, 2020, 4. 10. Investments in which Milestone Scientific can exercise significant influence, but do not may 6. 11. Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from two seven 12. Patents are recorded at cost to prepare and file the applicable documents with the US Patent Office, or internationally with the applicable governmental office in the respective country. The costs related to these patents are being amortized using the straight-line method over the estimated useful life of the patent. Patents and other developed technology acquired from another business entity will be amortized based on the estimated useful life of the patent. These patents and developed technology are recorded at the acquisition cost. 13. Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not ● significant under performance relative to expected historical or projected future operating results; ● significant changes in the manner of our use of the acquired assets or the strategy for our overall business; ● significant negative industry or economic trends; and ● significant technological changes, which would render the technology obsolete. Recoverability of assets that will continue to be used in the Company's operations is measured by comparing the carrying value to the future net undiscounted cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future revenues, driven by market growth rates, and estimated future costs. 14. On April 27, 2020, March 27, 2020. 15. Research and development costs, which consist principally of new product development costs payable to third 16. Milestone Scientific accounts for income taxes pursuant to the asset and liability method which requires deferred income tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. See Note 10. On June 30, 2021 December 31, 2020 2017, 2018, 2019 17. Milestone Scientific presents “basic” earnings (loss) per common share applicable to common stockholders and, if applicable, “diluted” earnings (loss) per common share applicable to common stockholders pursuant to the provisions of ASC 260, Since Milestone Scientific had net losses in the six June 30, 2021, 2020, not June 30, 2021, 2020, 18. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). We are required to classify fair value measurements in one ● Level 1 ● Level 2 1 ● Level 3 Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and may June 30, 2021 December 31, 2020, not 19. Milestone Scientific accounts for stock-based compensation under ASC 718, 718” 718 20. At the inception of an arrangement, we determine whether an arrangement is, or contains, a lease. An arrangement is, or contains, a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Leases with a term greater than one not 12 not Finance and operating lease right-of-use assets represent the Company’s right to use an underlying asset over the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. These assets and obligations are recognized at the lease commencement date based on the present value of lease payments, net of incentives, over the lease term. The interest rate implicit in our leases is typically not We evaluate the classification of our leases as either finance leases or operating leases. Leases that are economically similar to the purchase of assets are generally classified as finance leases; otherwise, the leases are classified as operating leases. Lease cost for our operating leases is recognized on a straight-line basis over the lease term. Included in lease cost are any variable lease payments incurred in the period that are not 12 14. 22. Recently Adopted Accounting Pronouncements In December 2019, 2019 12, 740 2019 12 December 15, 2020. January 1, 2021, not Recently Issued Accounting Pronouncements In June 2016, No.2016 13, 326 December 15, 2022. In January 2020, 2020 01, 321 323 815 2020 01 December 15, 2021, not In August 2020, 2020 06, 470 20 815 40 2020 06 December 15, 2021, not In May 2021, 2021 04, 260 470 50 718 815 40 1 2 January 1, 2022, January 1, 2022. 2021 04

Note 4 - Inventories

Note 4 - Inventories	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 4 Inventories consist of the following: June 30, 2021 December 31, 2020 Dental finished goods, net $ 764,434 $ 1,888,141 Medical finished goods, net 533,633 200,327 Component parts and other materials 181,324 331,711 Total inventories $ 1,479,391 $ 2,420,179 On June 30, 2021 December 31, 2020

Note 5 - Advances on Contracts

Note 5 - Advances on Contracts	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Advances to Contract Manufacturer [Text Block]	NOTE 5 The advances on contracts represent funding of future STA inventory purchases, epidural instruments, and epidural replacements parts. The balance of the advances as of June 30, 2021 December 31, 2020

Note 6 - Investment in and Tran

Note 6 - Investment in and Transactions With Equity Investees	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	NOTE 6 Milestone China Ltd. Ownership In June 2014, In first 2020, However, as of the filing date of this Quarterly Report, due to the COVID- 19 not may Milestone Scientific, in previous years, reduced its investment in Milestone China to zero and had accumulated losses over the investment balance of approximately $ December 31, 2020, For the three six June 30, 2021, not three six June 30, 2020. June 30, 2021, $270,864 June 30, 2021. Related Party Transactions Milestone China Distribution Agreement Milestone China is Milestone Scientific’s exclusive distributor in China. During 2017 2018, 2018, United Systems, Inc. Agreement In April 2020, 13 2018, not April 2020, April 23, 2020, June 2020, July 2020. Advanced Cosmetics Systems Agreement In May 2020, one On May 18, 2021, Gross Profit Deferral Due to timing differences of when the inventory sold to Milestone China is recognized and when Milestone China sells the acquired inventory to third 323 third At June 30 ,2021 December 31, 2020, $337,000 three six June 30, 2021 2020

Note 7 - Patents

Note 7 - Patents	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	NOTE 7 June 30, 2021 Cost Accumulated Amortization Net Patents-foundation intellectual property $ 1,377,863 $ (1,071,319 ) $ 306,544 Total $ 1,377,863 $ (1,071,319 ) $ 306,544 December 31, 2020 Cost Accumulated Amortization Net Patents-foundation intellectual property $ 1,377,863 $ (1,048,614 ) $ 329,249 Total $ 1,377,863 $ (1,048,614 ) $ 329,249 Patents are amortized utilizing the straight-line method over estimated useful lives ranging from 3 to 20 years. Amortization expense was approximately $11,000 and $22,000 for the three six June 30, 2021, 2020,

Note 8 - Note Payable

Note 8 - Note Payable	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	NOTE 8 On April 27, 2020, March 27, 2020. 2.5 seven eight The Loan matures on April 27, 2022, 1.00% November 26, 2020. April 27, 2022, not may no may February 15, 2020. During the quarter ending June 30, 2021,

Note 9 - Stockholders' Equity

Note 9 - Stockholders' Equity	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 9 Public Offering and Private Placement In the second 2020, two April 2020, three June 2020, second three Warrants The following table summarizes information about shares issuable under warrants outstanding as of June 30, 2021 Warrant shares outstanding Weighted Average exercise price Weighted Average remaining life Intrinsic value Outstanding at January 1, 2021 6,369,396 $ 1.97 $ 2.48 $ 2,784,117 Issued - Exercised (2,004,926 ) 1.57 - Expired or cancelled - - - - Outstanding and exercisable at June 30, 2021 4,364,470 $ 2.15 $ 2.01 $ 1,796,413 The following table summarizes information about shares issuable under warrants outstanding as of June 30, 2020 Warrant shares outstanding Weighted Average exercise price Weighted Average remaining life Intrinsic value Outstanding at January 1, 2020 1,074,171 $ 0.50 $ 4.10 $ 956,012 Issued 6,459,000 2.01 3.00 - Exercised (1,081,475 ) 0.88 - - Expired or cancelled - - - - Outstanding and exercisable at June 30, 2020 6,451,696 $ 1.95 $ 2.98 $ 2,430,184 Shares to Be Issued As of June 30, 2021 2020 2,370,345 As of June 30, 2021 2020 The following table summarizes information about shares to be issued on June 30, 2021 2020 June 30, 2021 June 30, 2020 Shares-to-be-issued, outstanding January 1, 2021 and 2020, respectively 2,428,329 2,375,760 Granted in current period 33,238 358,482 Issued in current period (53,416 ) (214,612 ) Shares-to be issued outstanding June 30, 2021 and 2020, respectively 2,408,151 2,519,630 Stock Option Plans In June 2011, 2011 "2011 2016 three five June 30, 2021, December 31, 2020, The Milestone Scientific Inc. 2020 "2020 June 2031. may not three five On April 8, 2021, April 23, 2021, five ten 2020 Milestone Scientific recognizes compensation expense over the requisite service period and in the case of performance-based options over the period of the expected performance. For the six June 30, 2021 2020, $286,00 June 30, 2021 A summary of option activity for employees under the plans and changes during the six June 30, 2021 2020 Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding January 1, 2021 1,953,443 1.88 3.09 476,964 Granted 2,032,175 2.48 - - Exercised during 2021 (435,558 ) 1.58 - - Forfeited or expired - - - - Options outstanding June 30, 2021 3,550,060 2.26 7.00 188,018 Exercisable, June 30, 2021 745,092 1.93 2.41 124,701 Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding January 1, 2020 1,212,442 1.71 2.40 - Granted - - - - Exercised during 2020 - - - - Forfeited or expired - - - - 1,212,442 1.71 2.40 - Exercisable, June 30, 2020 1,117,829 1.84 1.84 - The Company used the following assumptions to calculate the fair value of the stock option grants using the Black-Scholes option pricing model on the measurement date during the six June 30, 2021 .19% 3 0% A summary of option activity for non-employees under the plans and changes during the six June 30, 2021 2020 Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding January 1, 2021 74,997 1.41 3.18 54,748 Granted 16,666 4.30 Exercised during 2021 - - - - Options outstanding June 30, 2021 91,663 1.69 2.87 77664 Exercisable, June 30, 2021 52,769 1.68 2.12 50,658 Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding January 1, 2020 49,998 1.87 2.94 - Granted 8,333 1.65 - Exercised during 2020 - - - - Options outstanding June 30, 2020 58,331 1.87 2.94 Exercisable, June 30, 2020 41,663 1.71 2.03 84,579 The fair value of the non-employee options was estimated on the date of grant using the Black Scholes option-pricing model at the date of grant. For the three six June 30, 2021, six June 30, 2020, The Company used the following assumptions to calculate the fair value of the stock option grants using the Black-Scholes option pricing model on the measurement date during the six June 30, 2021, The information below summarizes the restricted stock activity for the six June 30, 2021: Restricted Stock Awards Shares Weighted Average Grant-Date Fair Value per Award Non-vested as December 31, 2020 - $ - Granted 79,365 2.52 Vested - - Non-vested as June 30, 2021 79,365 $ 2.52 For the three six June 30, 2021, $20,833

Note 10 - Income Taxes

Note 10 - Income Taxes	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 10 The utilization of Milestone Scientific's net operating losses may 382 may

Note 11 - Segment and Geographi

Note 11 - Segment and Geographic Data	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Product Sales and Significant Customers and Vendors Disclosure [Text Block]	NOTE 11 We conduct our business through two reportable segments: Dental and Medical. These segments offer different products and services to different customer bases. The Company provides general corporate services to its segments; however, these services are not The following tables present information about our reportable and operating segments: Net Sales: Three months ended June 30, 2021 Three months ended June 30, 2020 Six months ended June 30, 2021 Six months ended June 30, 2020 Dental $ 2,404,738 $ 165,674 $ 5,258,395 $ 1,969,260 Medical 21,000 2,000 92,050 9,800 Total net sales $ 2,425,738 $ 167,674 $ 5,350,445 $ 1,979,060 Operating Income (Loss): Three months ended June 30, 2021 Three months ended June 30, 2020 Six months ended June 30, 2021 Six months ended June 30, 2020 Dental $ 524,798 $ (650,236 ) $ 1,650,831 $ (223,856 ) Medical (1,135,001 ) (814,429 ) (2,030,720 ) (1,484,241 ) Corporate (2,262,369 ) (1,708,225 ) (3,477,056 ) (3,073,399 ) Total operating loss $ (2,872,572 ) $ (3,172,890 ) $ (3,856,945 ) $ (4,781,496 ) Depreciation and Amortization Three months ended June 30, 2021 Three months ended June 30, 2020 Six months ended June 30, 2021 Six months ended June 30, 2020 Dental $ 860 $ 3,101 $ 2,566 $ 8,800 Medical 1,165 621 5,016 4,333 Corporate 12,809 17,416 28,178 45,224 Total depreciation and amortization $ 14,834 $ 21,138 $ 35,760 $ 54,457 Income (loss) before taxes and equity in earnings of affiliates: Three months ended June 30, 2021 Three months ended June 30, 2020 Six months ended June 30, 2021 Six months ended June 30, 2020 Dental $ 598,166 $ (651,384 ) $ 1,723,284 $ (225,845 ) Medical (1,136,271 ) (815,391 ) (2,033,260 ) (1,486,310 ) Corporate (2,062,748 ) (1,710,177 ) (3,277,785 ) (3,077,500 ) Total loss before taxes and equity in earnings of affiliate $ (2,600,853 ) $ (3,176,952 ) $ (3,587,761 ) $ (4,789,655 ) Total Assets: June 30, 2021 December 31, 2020 Dental $ 6,639,102 $ 6,035,645 Medical 1,196,977 923,658 Corporate 13,223,587 12,612,147 Total assets $ 21,059,666 $ 19,571,450 The following table presents information about our operations by geographic area for three June 30, 2021 2020 Three Months Ended June 30, 2021 Three Months Ended June 30, 2020 Dental Medical Grand Total Dental Medical Grand Total Domestic: US Instruments $ 178,752 $ - $ 178,752 $ - $ - $ - Handpieces 802,916 - 802,916 36,812 2,000 38,812 Accessories 18,974 18,974 1,542 1,542 Total Domestic US $ 1,000,642 $ - $ 1,000,642 $ 38,354 $ 2,000 $ 40,354 International: Rest of World Dental Medical Grand Total Dental Medical Grand Total Instruments 156,588 $ 15,500 $ 172,088 $ 31,800 $ - $ 31,800 Handpieces 709,624 5,500 715,124 87,632 - 87,632 Accessories 12,548 - 12,548 7,888 - 7,888 Total International $ 878,761 $ 21,000 $ 899,761 $ 127,320 $ - $ 127,320 International: China Dental Medical Grand Total Dental Medical Grand Total Instruments $ 78,000 $ - $ 78,000 $ - $ - $ - Handpieces 447,336 - 447,336 - - - Other - - - - Total International 525,336 - 525,336 - - - Total Product Sales $ 2,404,738 $ 21,000 $ 2,425,738 $ 165,674 $ 2,000 $ 167,674 The following table presents information about our operations by geographic area for six June 30, 2021 2020 Six Months Ended June 30, 2021 Six Months Ended June 30, 2020 Dental Medical Total Dental Medical Total Domestic: US Instruments $ 354,768 $ - $ 354,768 $ 525 $ - $ 525 Handpieces 1,597,900 8,150 1,606,050 633,490 2,000 635,490 Accessories 36,882 36,882 21,590 21,590 Total Domestic US $ 1,989,550 $ 8,150 $ 1,997,700 $ 655,605 $ 2,000 $ 657,605 International: Rest of World Dental Medical Total Dental Medical Total Instruments $ 539,841 $ 58,000 $ 597,841 $ 274,304 $ 7,600 $ 281,904 Handpieces 1,663,559 25,900 1,689,459 1,017,923 200 1,018,123 Accessories 33,109 - 33,109 21,428 - 21,428 Total International $ 2,236,509 $ 83,900 $ 2,320,409 $ 1,313,655 $ 7,800 $ 1,321,455 International: China Dental Medical Total Dental Medical Total Instruments $ 228,000 $ - $ 228,000 $ - $ - $ - Handpieces 804,336 - 804,336 - - - Other - - - - Total International 1,032,336 - $ 1,032,336 $ - $ - $ - Total Product Sales $ 5,258,395 $ 92,050 $ 5,350,445 $ 1,969,260 $ 9,800 $ 1,979,060

Note 12 - Concentrations

Note 12 - Concentrations	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	NOTE 12 Milestone Scientific has informal arrangements with third For the three June 30, 2021, six June 30, 2021, For the three June 30, 2020, six June 30, 2020, Accounts receivable for domestic and international distributors was approximately 41% and 59%, respectively, of Milestone Scientific's gross accounts receivable as of June 30, 2021. June 30, 2020.

Note 13 - Related Party Transac

Note 13 - Related Party Transactions	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 13 United Systems Milestone Scientific has a manufacturing agreement with United Systems (whose controlling shareholder, Tom Cheng, is a significant stockholder of Milestone Scientific), the sole manufacturer of its handpieces, pursuant to which it manufactures products under specific purchase orders, but without minimum purchase commitments. Purchases from this manufacturer were approximately $384,000 and $751,000 for the three June 30, 2021 2020, June 30, 2021, December 31, 2020, June 30, 2021 December 31, 2020, June 2021, ten On April 29, 2020, 6. Milestone China See Note 6. Other As of June 30, 2021 December 31, 2020, $0.00 The Company engaged Mr. Trombetta as a consultant for a period of twelve October 1, 2020 September 30, 2021), three six June 30, 2021 $30,000, In August 2016, three six June 30, 2021 2020, In January 2017, twelve $20,000, three six June 30, 2020, September 30, 2020. The Director of Clinical Affairs’ royalty fee was approximately $111,000 and $97,000 for the three June 30, 2021 2020, $19,000 six June 30, 2021 2020, three six June 30, 2021 2020, June 30, 2021 December 31, 2020, 14 3

Note 14 - Commitments

Note 14 - Commitments	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 14 ( 1 third January 2021, 2021. June 30, 2021 As of June 30, 2021 In February 2021, April 2021. June 30, 2021 1,185 ( 2 Operating Leases In June 2015, January 31, 2020 not not not In August 2019, not seven January 8, 2020. April 1, 2020 January 1 not As of June 30, 2021, June 30, 2021, December 31, 2020, December 31, 2020, Cash flow information related to the Company's right-of-use assets and related lease liabilities were as follows: Three Months Ended June 30, Six Months Ended June 30, Lease cost 2021 2020 2021 2020 Cash paid for operating lease liabilities 31,303 30,820 62,606 48,084 Cash paid for finance lease liabilities 2,685 2,685 5,370 4,937 Right-of-use assets obtained in exchange for new operating lease liabilities (1) - - - 663,009 Property and equipment obtained in exchange for new finance lease liabilities - - - 43,242 (1) For the six months ended June 30, 2021, the balance includes operating leases existing as of the adoption of ASC 842 on January 1, 2021 Weighted-average remaining lease term - operating leases (years) - - 5.8 6.8 Weighted-average remaining lease term- finance leases (years) - - 3.6 4.60 ( 3 The technology underlying the Safety Wand CompuFlo CompuDent January 1, 2005, 2.5% May 9, 2027 – 13 On March 2, 2021, May 9, 2027, February 25, 2021 May 9, 2027 Succession Agreement With respect to (i) the Employment Agreement dated as of July 10, 2017 July 10, 2017 ( 9.5 May 19, 2021.

Note 15 - Subsequent Events

Note 15 - Subsequent Events	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 15— On May 12, 2021, May 24, 2021, July 2, 2021,

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	1. The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), Milestone Advanced Cosmetic (majority owned), and Milestone Medical (majority owned). All significant, intra-entity transactions and balances have been eliminated in consolidation.
Basis of Accounting, Policy [Policy Text Block]	2. The unaudited condensed consolidated financial statements of Milestone Scientific have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information with the instructions for Form 10 8 X. not not may December 31, 2020, 10
Reclassification, Comparability Adjustment [Policy Text Block]	3. Certain reclassification has been made to the 2020 2021 no
Use of Estimates, Policy [Policy Text Block]	4. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the allowance for doubtful accounts, inventory valuation, cash flow assumptions regarding evaluations for impairment of long-lived assets and going concern considerations, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.
Revenue [Policy Text Block]	5. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To perform revenue recognition for customer arrangements the Company performs the following five i. identification of the promised goods or services in the contract; ii. determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; iii. measurement of the transaction price, including the constraint on variable consideration; iv. allocation of the transaction price to the performance obligations based on estimated standalone selling prices; and selling prices; and v. recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606, The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products through a global distribution network and that includes both exclusive and non-exclusive distribution agreements with related and third Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon date of shipment. For certain arrangements where the shipping terms are freight-on-board (FOB) shipping, revenue is recognized upon delivery. The Company has no Sales Returns The Company records allowances for product returns as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including the customers’ return rights and the Company’s historical experience with returns and the amount of product in the distribution channel not may Financing and Payment Our payment terms differ by geography and customer, but payment is generally required within 90 Disaggregation of Revenue We operate in two 11 six June 30, 2021
Consolidation, Variable Interest Entity, Policy [Policy Text Block]	6. A variable interest entity ("VIE") is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE. Because Milestone Scientific has a variable interest in Milestone China it considered the guidance in ASC 810, ● Power Criterion: The power to direct the activities that most significantly impact the entity’s economic performance; and ● Losses/Benefits Criterion: The obligation to absorb losses that could potentially be significant or the right to receive benefits that could potentially be significant to the VIE. Milestone Scientific does not not not 810. 6.
Cash and Cash Equivalents, Policy [Policy Text Block]	7. Milestone Scientific considers all highly liquid investments purchased with an original maturity of three June 30, 2021, December 31, 2020 may
Trade and Other Accounts Receivable, Unbilled Receivables, Policy [Policy Text Block]	8. Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the inability of its customers to make payments on amounts billed. Most credit sales are due within 90 not June 30, 2021 December 31, 2020
Inventory, Policy [Policy Text Block]	9. Inventories principally consist of finished goods and component parts stated at the lower of cost ( first first not June 30,2021, December 31, 2020, 4.
Equity Method Investments [Policy Text Block]	10. Investments in which Milestone Scientific can exercise significant influence, but do not may 6.
Property, Plant and Equipment, Policy [Policy Text Block]	11. Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from two seven
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	12. Patents are recorded at cost to prepare and file the applicable documents with the US Patent Office, or internationally with the applicable governmental office in the respective country. The costs related to these patents are being amortized using the straight-line method over the estimated useful life of the patent. Patents and other developed technology acquired from another business entity will be amortized based on the estimated useful life of the patent. These patents and developed technology are recorded at the acquisition cost.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	13. Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not ● significant under performance relative to expected historical or projected future operating results; ● significant changes in the manner of our use of the acquired assets or the strategy for our overall business; ● significant negative industry or economic trends; and ● significant technological changes, which would render the technology obsolete. Recoverability of assets that will continue to be used in the Company's operations is measured by comparing the carrying value to the future net undiscounted cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future revenues, driven by market growth rates, and estimated future costs.
Debt, Policy [Policy Text Block]	14. On April 27, 2020, March 27, 2020.
Research and Development Expense, Policy [Policy Text Block]	15. Research and development costs, which consist principally of new product development costs payable to third
Income Tax, Policy [Policy Text Block]	16. Milestone Scientific accounts for income taxes pursuant to the asset and liability method which requires deferred income tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. See Note 10. On June 30, 2021 December 31, 2020 2017, 2018, 2019
Earnings Per Share, Policy [Policy Text Block]	17. Milestone Scientific presents “basic” earnings (loss) per common share applicable to common stockholders and, if applicable, “diluted” earnings (loss) per common share applicable to common stockholders pursuant to the provisions of ASC 260, Since Milestone Scientific had net losses in the six June 30, 2021, 2020, not June 30, 2021, 2020,
Fair Value of Financial Instruments, Policy [Policy Text Block]	18. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). We are required to classify fair value measurements in one ● Level 1 ● Level 2 1 ● Level 3 Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and may June 30, 2021 December 31, 2020, not
Share-based Payment Arrangement [Policy Text Block]	19. Milestone Scientific accounts for stock-based compensation under ASC 718, 718” 718
Lessee, Leases [Policy Text Block]	20. At the inception of an arrangement, we determine whether an arrangement is, or contains, a lease. An arrangement is, or contains, a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Leases with a term greater than one not 12 not Finance and operating lease right-of-use assets represent the Company’s right to use an underlying asset over the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. These assets and obligations are recognized at the lease commencement date based on the present value of lease payments, net of incentives, over the lease term. The interest rate implicit in our leases is typically not We evaluate the classification of our leases as either finance leases or operating leases. Leases that are economically similar to the purchase of assets are generally classified as finance leases; otherwise, the leases are classified as operating leases. Lease cost for our operating leases is recognized on a straight-line basis over the lease term. Included in lease cost are any variable lease payments incurred in the period that are not 12 14.
New Accounting Pronouncements, Policy [Policy Text Block]	22. Recently Adopted Accounting Pronouncements In December 2019, 2019 12, 740 2019 12 December 15, 2020. January 1, 2021, not Recently Issued Accounting Pronouncements In June 2016, No.2016 13, 326 December 15, 2022. In January 2020, 2020 01, 321 323 815 2020 01 December 15, 2021, not In August 2020, 2020 06, 470 20 815 40 2020 06 December 15, 2021, not In May 2021, 2021 04, 260 470 50 718 815 40 1 2 January 1, 2022, January 1, 2022. 2021 04

Note 4 - Inventories (Tables)

Note 4 - Inventories (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, 2021 December 31, 2020 Dental finished goods, net $ 764,434 $ 1,888,141 Medical finished goods, net 533,633 200,327 Component parts and other materials 181,324 331,711 Total inventories $ 1,479,391 $ 2,420,179

Note 7 - Patents (Tables)

Note 7 - Patents (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	June 30, 2021 Cost Accumulated Amortization Net Patents-foundation intellectual property $ 1,377,863 $ (1,071,319 ) $ 306,544 Total $ 1,377,863 $ (1,071,319 ) $ 306,544 December 31, 2020 Cost Accumulated Amortization Net Patents-foundation intellectual property $ 1,377,863 $ (1,048,614 ) $ 329,249 Total $ 1,377,863 $ (1,048,614 ) $ 329,249

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrant shares outstanding Weighted Average exercise price Weighted Average remaining life Intrinsic value Outstanding at January 1, 2021 6,369,396 $ 1.97 $ 2.48 $ 2,784,117 Issued - Exercised (2,004,926 ) 1.57 - Expired or cancelled - - - - Outstanding and exercisable at June 30, 2021 4,364,470 $ 2.15 $ 2.01 $ 1,796,413 Warrant shares outstanding Weighted Average exercise price Weighted Average remaining life Intrinsic value Outstanding at January 1, 2020 1,074,171 $ 0.50 $ 4.10 $ 956,012 Issued 6,459,000 2.01 3.00 - Exercised (1,081,475 ) 0.88 - - Expired or cancelled - - - - Outstanding and exercisable at June 30, 2020 6,451,696 $ 1.95 $ 2.98 $ 2,430,184
Deferred Compensation Arrangement with Individual, Share-based Payments [Table Text Block]	June 30, 2021 June 30, 2020 Shares-to-be-issued, outstanding January 1, 2021 and 2020, respectively 2,428,329 2,375,760 Granted in current period 33,238 358,482 Issued in current period (53,416 ) (214,612 ) Shares-to be issued outstanding June 30, 2021 and 2020, respectively 2,408,151 2,519,630
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding January 1, 2021 1,953,443 1.88 3.09 476,964 Granted 2,032,175 2.48 - - Exercised during 2021 (435,558 ) 1.58 - - Forfeited or expired - - - - Options outstanding June 30, 2021 3,550,060 2.26 7.00 188,018 Exercisable, June 30, 2021 745,092 1.93 2.41 124,701 Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding January 1, 2020 1,212,442 1.71 2.40 - Granted - - - - Exercised during 2020 - - - - Forfeited or expired - - - - 1,212,442 1.71 2.40 - Exercisable, June 30, 2020 1,117,829 1.84 1.84 - Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding January 1, 2021 74,997 1.41 3.18 54,748 Granted 16,666 4.30 Exercised during 2021 - - - - Options outstanding June 30, 2021 91,663 1.69 2.87 77664 Exercisable, June 30, 2021 52,769 1.68 2.12 50,658 Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding January 1, 2020 49,998 1.87 2.94 - Granted 8,333 1.65 - Exercised during 2020 - - - - Options outstanding June 30, 2020 58,331 1.87 2.94 Exercisable, June 30, 2020 41,663 1.71 2.03 84,579
Restricted Stock [Member]
Notes Tables
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Restricted Stock Awards Shares Weighted Average Grant-Date Fair Value per Award Non-vested as December 31, 2020 - $ - Granted 79,365 2.52 Vested - - Non-vested as June 30, 2021 79,365 $ 2.52

Note 11 - Segment and Geograp_2

Note 11 - Segment and Geographic Data (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Net Sales: Three months ended June 30, 2021 Three months ended June 30, 2020 Six months ended June 30, 2021 Six months ended June 30, 2020 Dental $ 2,404,738 $ 165,674 $ 5,258,395 $ 1,969,260 Medical 21,000 2,000 92,050 9,800 Total net sales $ 2,425,738 $ 167,674 $ 5,350,445 $ 1,979,060 Operating Income (Loss): Three months ended June 30, 2021 Three months ended June 30, 2020 Six months ended June 30, 2021 Six months ended June 30, 2020 Dental $ 524,798 $ (650,236 ) $ 1,650,831 $ (223,856 ) Medical (1,135,001 ) (814,429 ) (2,030,720 ) (1,484,241 ) Corporate (2,262,369 ) (1,708,225 ) (3,477,056 ) (3,073,399 ) Total operating loss $ (2,872,572 ) $ (3,172,890 ) $ (3,856,945 ) $ (4,781,496 ) Depreciation and Amortization Three months ended June 30, 2021 Three months ended June 30, 2020 Six months ended June 30, 2021 Six months ended June 30, 2020 Dental $ 860 $ 3,101 $ 2,566 $ 8,800 Medical 1,165 621 5,016 4,333 Corporate 12,809 17,416 28,178 45,224 Total depreciation and amortization $ 14,834 $ 21,138 $ 35,760 $ 54,457 Income (loss) before taxes and equity in earnings of affiliates: Three months ended June 30, 2021 Three months ended June 30, 2020 Six months ended June 30, 2021 Six months ended June 30, 2020 Dental $ 598,166 $ (651,384 ) $ 1,723,284 $ (225,845 ) Medical (1,136,271 ) (815,391 ) (2,033,260 ) (1,486,310 ) Corporate (2,062,748 ) (1,710,177 ) (3,277,785 ) (3,077,500 ) Total loss before taxes and equity in earnings of affiliate $ (2,600,853 ) $ (3,176,952 ) $ (3,587,761 ) $ (4,789,655 ) Total Assets: June 30, 2021 December 31, 2020 Dental $ 6,639,102 $ 6,035,645 Medical 1,196,977 923,658 Corporate 13,223,587 12,612,147 Total assets $ 21,059,666 $ 19,571,450
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Three Months Ended June 30, 2021 Three Months Ended June 30, 2020 Dental Medical Grand Total Dental Medical Grand Total Domestic: US Instruments $ 178,752 $ - $ 178,752 $ - $ - $ - Handpieces 802,916 - 802,916 36,812 2,000 38,812 Accessories 18,974 18,974 1,542 1,542 Total Domestic US $ 1,000,642 $ - $ 1,000,642 $ 38,354 $ 2,000 $ 40,354 International: Rest of World Dental Medical Grand Total Dental Medical Grand Total Instruments 156,588 $ 15,500 $ 172,088 $ 31,800 $ - $ 31,800 Handpieces 709,624 5,500 715,124 87,632 - 87,632 Accessories 12,548 - 12,548 7,888 - 7,888 Total International $ 878,761 $ 21,000 $ 899,761 $ 127,320 $ - $ 127,320 International: China Dental Medical Grand Total Dental Medical Grand Total Instruments $ 78,000 $ - $ 78,000 $ - $ - $ - Handpieces 447,336 - 447,336 - - - Other - - - - Total International 525,336 - 525,336 - - - Total Product Sales $ 2,404,738 $ 21,000 $ 2,425,738 $ 165,674 $ 2,000 $ 167,674 Six Months Ended June 30, 2021 Six Months Ended June 30, 2020 Dental Medical Total Dental Medical Total Domestic: US Instruments $ 354,768 $ - $ 354,768 $ 525 $ - $ 525 Handpieces 1,597,900 8,150 1,606,050 633,490 2,000 635,490 Accessories 36,882 36,882 21,590 21,590 Total Domestic US $ 1,989,550 $ 8,150 $ 1,997,700 $ 655,605 $ 2,000 $ 657,605 International: Rest of World Dental Medical Total Dental Medical Total Instruments $ 539,841 $ 58,000 $ 597,841 $ 274,304 $ 7,600 $ 281,904 Handpieces 1,663,559 25,900 1,689,459 1,017,923 200 1,018,123 Accessories 33,109 - 33,109 21,428 - 21,428 Total International $ 2,236,509 $ 83,900 $ 2,320,409 $ 1,313,655 $ 7,800 $ 1,321,455 International: China Dental Medical Total Dental Medical Total Instruments $ 228,000 $ - $ 228,000 $ - $ - $ - Handpieces 804,336 - 804,336 - - - Other - - - - Total International 1,032,336 - $ 1,032,336 $ - $ - $ - Total Product Sales $ 5,258,395 $ 92,050 $ 5,350,445 $ 1,969,260 $ 9,800 $ 1,979,060

Note 14 - Commitments (Tables)

Note 14 - Commitments (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Lease, Cost and Other Information [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, Lease cost 2021 2020 2021 2020 Cash paid for operating lease liabilities 31,303 30,820 62,606 48,084 Cash paid for finance lease liabilities 2,685 2,685 5,370 4,937 Right-of-use assets obtained in exchange for new operating lease liabilities (1) - - - 663,009 Property and equipment obtained in exchange for new finance lease liabilities - - - 43,242 (1) For the six months ended June 30, 2021, the balance includes operating leases existing as of the adoption of ASC 842 on January 1, 2021 Weighted-average remaining lease term - operating leases (years) - - 5.8 6.8 Weighted-average remaining lease term- finance leases (years) - - 3.6 4.60

Note 1 - Organization and Bus_2

Note 1 - Organization and Business (Details Textual)	1 Months Ended		6 Months Ended
	Jun. 30, 2020USD ($)	Apr. 30, 2020USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Number of Countries in which Entity Operates			60
Proceeds from Issuance of Common Stock			$ 0	$ 18,003,037
Cash and Cash Equivalents, at Carrying Value, Ending Balance			15,977,330		$ 14,223,917
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total			$ 1,753,413	$ 15,093,945
April 6, 2020 Public Offering [Member]
Proceeds from Issuance of Common Stock		$ 4,600,000
June 30, 2020 Public Offering [Member]
Proceeds from Issuance of Common Stock	$ 13,400,000

Note 2 - Liquidity and Uncert_2

Note 2 - Liquidity and Uncertainties (Details Textual) - USD ($)	1 Months Ended		3 Months Ended		6 Months Ended
	Jun. 30, 2020	Apr. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Retained Earnings (Accumulated Deficit), Ending Balance			$ (104,539,294)		$ (104,539,294)		$ (100,885,957)
Net Income (Loss) Attributable to Parent, Total			(2,680,468)	$ (3,166,464)	(3,653,337)	$ (4,766,679)
Proceeds from Issuance of Common Stock					0	18,003,037
Cash and Cash Equivalents, at Carrying Value, Ending Balance			$ 15,977,330		15,977,330		$ 14,223,917
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total					$ 1,753,413	$ 15,093,945
April 6, 2020 Public Offering [Member]
Proceeds from Issuance of Common Stock		$ 4,600,000
June 30, 2020 Public Offering [Member]
Proceeds from Issuance of Common Stock	$ 13,400,000

Note 3 - Summary of Significa_2

Note 3 - Summary of Significant Accounting Policies (Details Textual)	Apr. 27, 2020USD ($)	Jun. 30, 2021USD ($)shares	Jun. 30, 2020USD ($)shares	Dec. 31, 2020USD ($)
Number of Operating Segments		2
Short-term Investments, Total		$ 14,800,000		$ 13,100,000
Accounts Receivable, Allowance for Credit Loss, Ending Balance		280,864		10,000
Inventory Valuation Reserves, Ending Balance		450,000		453,000
Proceeds from Notes Payable, Total		0	$ 272,099
Unrecognized Tax Benefits, Ending Balance		0		$ 0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total		$ 0
Open Tax Year		2017 2018 2019
Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares		8,015,193	7,686,628
Paycheck Protection Program CARES Act [Member]
Proceeds from Notes Payable, Total	$ 276,000
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)		2 years
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)		7 years

Note 4 - Inventories (Details T

Note 4 - Inventories (Details Textual) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Inventory Valuation Reserves, Ending Balance	$ 450,000	$ 453,000
Slow Moving Medical Finished Goods [Member]
Inventory Valuation Reserves, Ending Balance	$ 450,000	450,000
Slow Moving Dental Finished Goods [Member]
Inventory Valuation Reserves, Ending Balance		$ 3,000

Note 4 - Inventories - Summary

Note 4 - Inventories - Summary of Inventories (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Component parts and other materials	$ 181,324	$ 331,711
Total inventories	1,479,391	2,420,179
Dental Segment [Member]
Finished goods, net	764,434	1,888,141
Medical Segment [Member]
Finished goods, net	$ 533,633	$ 200,327

Note 5 - Advances on Contracts

Note 5 - Advances on Contracts (Details Textual) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Advances on Inventory Purchases	$ 1,393,817	$ 414,202

Note 6 - Investment in and Tr_2

Note 6 - Investment in and Transactions With Equity Investees (Details Textual) - USD ($)	Apr. 30, 2020	Apr. 29, 2020	Jul. 31, 2020	May 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2018	Dec. 31, 2020	Apr. 23, 2020	Jun. 30, 2014
Income (Loss) from Equity Method Investments, Total					$ (95,857)	$ 0	$ (94,556)	$ 0
Acquisition of Advanced Cosmetic Systems [Member]
Business Acquisition, Percentage of Voting Interests Acquired				50.00%
Business Combination, Consideration Transferred, Total				$ 900,000
Business Combination, Percentage of Ownership Interest that Seller of Ownership Interest May Repurchase Within One Year of Sale Date				50.00%
Business Combination, Price at Which the Additional Ownership Interest Acquired May Repurchased Within One Year of Sale Date				$ 900,000
Business Combination, Step Acquisition, Equity Interest in Acquiree, including Subsequent Acquisition, Percentage, Total				100.00%
Manufacturing Agreement for Handpieces [Member]
Related Party Transaction, Purchases from Related Party	$ 370,260	$ 370,260			384,000	751,000
Sale Price in Cash [Member]
Related Party Transaction, Purchases from Related Party	100,000		$ 100,000
Sale Price in Share [Member]
Related Party Transaction, Purchases from Related Party	$ 170,260
Share Price (in dollars per share)											$ 1.59
Milestone China [Member]
Revenue from Related Parties					525,000	0	1	0
Contract with Customer, Liability, Total					178,000		178,000
Milestone China [Member]
Equity Method Investments												$ 1,000,000
Equity Method Investment, Ownership Percentage												40.00%
Financing Receivable, after Allowance for Credit Loss, Total									$ 2,800,000
Proceeds from Collection of Finance Receivables									$ 950,000
Due from Related Parties, Total										$ 1,400,000
Income (Loss) from Equity Method Investments, Total					$ 95,000	$ 95,000	$ 95,000	$ 95,000
Milestone China [Member] | Accounts Receivable from Related Parties [Member]
Equity Method Investment, Deferred Intercompany Profit (Loss)										243,000
Milestone Beijing [Member] | Milestone China [Member]
Equity Method Investment, Ownership Percentage												75.00%
Anhui [Member]
Equity Method Investments										0
Equity Method Investment, Ownership Percentage					28.40%		28.40%
Equity Method Investments, Accumulated Loss										$ 5,900,000

Note 7 - Patents (Details Textu

Note 7 - Patents (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Amortization of Intangible Assets, Total			$ 22,705	$ 26,506
Patents [Member]
Amortization of Intangible Assets, Total	$ 11,000	$ 22,000	$ 11,000	$ 22,000
Patents [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)			3 years
Patents [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)			20 years

Note 7 - Patents - Summary of P

Note 7 - Patents - Summary of Patents (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Patents, cost	$ 1,377,863	$ 1,377,863
Patents, accumulated amortization	(1,071,319)	(1,048,614)
Patents-foundation intellectual property	306,544	329,249
Foundation Intellectual Property Patents [Member]
Patents, cost	1,377,863	1,377,863
Patents, accumulated amortization	(1,071,319)	(1,048,614)
Patents-foundation intellectual property	$ 306,544	$ 329,249

Note 8 - Note Payable (Details

Note 8 - Note Payable (Details Textual) - USD ($)	Apr. 27, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Proceeds from Notes Payable, Total				$ 0	$ 272,099
Gain (Loss) on Extinguishment of Debt, Total		$ 276,180	$ 0	$ 276,180	$ 0
Paycheck Protection Program CARES Act [Member]
Proceeds from Notes Payable, Total	$ 276,000
Gain (Loss) on Extinguishment of Debt, Total		$ 276,000

Note 9 - Stockholders' Equity_2

Note 9 - Stockholders' Equity (Details Textual) - USD ($)	Apr. 23, 2021	Jun. 30, 2020	Apr. 30, 2020	Jun. 30, 2011	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 1.95			$ 2.15	$ 2.15	$ 1.95	$ 1.97	$ 0.50
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance (in shares)		2,519,630			2,408,151	2,408,151	2,519,630	2,428,329	2,375,760
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Amount Capitalized						$ 286,000	$ 48,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total					$ 3.5	$ 3.5
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)						4 years 4 months 24 days
Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)						2,032,175	0
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum						0.19%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum						1.15%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum						69.10%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum						94.00%
Share-based Payment Arrangement, Expense					$ 4,800	$ 15,000	$ 7,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate						0.00%
Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Employee [Member] | Maximum [Member]
Share Price (in dollars per share)					$ 3.79	$ 3.79
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)						6 years 6 months
Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Employee [Member] | Minimum [Member]
Share Price (in dollars per share)					2.46	$ 2.46
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)						3 years
Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Nonemployee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)						16,666	8,333
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum						86.97%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum						94.05%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)						5 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate						0.30%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate						0.00%
Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Nonemployee [Member] | Maximum [Member]
Share Price (in dollars per share)					4.30	$ 4.30
Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Nonemployee [Member] | Minimum [Member]
Share Price (in dollars per share)					$ 3.57	$ 3.57
Restricted Stock [Member]
Share-based Payment Arrangement, Expense					$ 20,833	$ 20,833
Stock Option Plan 2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)				2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)				4,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Period from Grant Date (Year)				3 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expire Period after Grant Date (Year)				5 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)					2,471,659	2,471,659		424,425
The 2020 Equity Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)						4,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)						3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)						5 years
Chief Executive Officer, Chief Financial Officer and Employees [Member]
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance (in shares)		2,370,345			2,264,127	2,264,127	2,370,345
Non-Employees [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)		149,285			144,024	144,024	149,285
Vice Chairman of the Board of Directors [Member] | The 2020 Equity Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	2,000,000
Warrants Associated With April 2020 Public Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			2,710,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 1.20
Warrants Associated With the June 2020 Public Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		3,749,000					3,749,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 2.60					$ 2.60
April 6, 2020 Public Offering [Member]
Proceeds from Issuance of Common Stock, Gross			$ 5,100,000
Stock Issued During Period, Shares, New Issues (in shares)			5,420,000
Share Price (in dollars per share)			$ 0.95
June 30, 2020 Public Offering [Member]
Proceeds from Issuance of Common Stock, Gross		$ 14,600,000
Stock Issued During Period, Shares, New Issues (in shares)		6,770,000
Share Price (in dollars per share)		$ 2.15					$ 2.15

Note 9 - Stockholders' Equity -

Note 9 - Stockholders' Equity - Warrants (Details) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Outstanding, number of shares (in shares)	6,369,396	1,074,171	1,074,171
Outstanding, weighted average exercise price (in dollars per share)	$ 1.97	$ 0.50	$ 0.50
Outstanding, weighted average remaining life (Year)	2 years 3 days	2 years 11 months 23 days	2 years 5 months 23 days	4 years 1 month 6 days
Outstanding, intrinsic value	$ 1,796,413	$ 2,430,184	$ 2,784,117	$ 956,012
Issued, number of shares (in shares)	0	6,459,000
Issued, weighted average exercise price (in dollars per share)		$ 2.01
Exercised, number of shares (in shares)	(2,004,926)	(1,081,475)
Exercised, weighted average exercise price (in dollars per share)	$ 1.57	$ 0.88
Expired or cancelled (in shares)	0	0
Expired or cancelled, weighted average exercise price (in dollars per share)	$ 0	$ 0
Issued, weighted average remaining life (Year)		3 years
Outstanding , number of shares (in shares)	4,364,470	6,451,696	6,369,396	1,074,171
Outstanding , weighted average exercise price (in dollars per share)	$ 2.15	$ 1.95	$ 1.97	$ 0.50

Note 9 - Stockholders' Equity_3

Note 9 - Stockholders' Equity - Summary of Shares to be Issued (Details) - shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Shares-to-be-issued, outstanding (in shares)	2,428,329	2,375,760
Granted in current period (in shares)	33,238	358,482
Issued in current period (in shares)	(53,416)	(214,612)
Shares-to be issued outstanding (in shares)	2,408,151	2,519,630

Note 9 - Stockholders' Equity_4

Note 9 - Stockholders' Equity - Summary of Option Activity for Employees and Non-employees (Details) - Share-based Payment Arrangement, Option [Member] - USD ($)	3 Months Ended	6 Months Ended		12 Months Ended
	Mar. 31, 2021	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement, Nonemployee [Member]
Number of options (in shares)	74,997	74,997	49,998	49,998
Weighted average exercise price, outstanding (in dollars per share)	$ 1.41	$ 1.41	$ 1.87	$ 1.87
Weighted average remaining contractual life, outstanding (Year)		2 years 10 months 13 days	2 years 11 months 8 days	3 years 2 months 4 days	2 years 11 months 8 days
Aggregate intrinsic value, outstanding	$ 77,664			$ 54,748	$ 0
Number of options granted (in shares)		16,666	8,333
Weighted average exercise price, granted (in dollars per share)		$ 4.30	$ 1.65
Number of options exercised (in shares)		0	0
Weighted average exercise price, exercised (in dollars per share)		$ 0	$ 0
Number of options exercisable (in shares)		52,769	41,663
Weighted average exercise price, exercisable (in dollars per share)		$ 1.68	$ 1.71
Weighted average remaining contractual life, exercisable (Year)		2 years 1 month 13 days	2 years 10 days
Aggregate intrinsic value, exercisable	$ 50,658		$ 84,579
Common stock issued to employee for stock options exercised (in shares)		0	0
Number of options (in shares)		91,663	58,331	74,997	49,998
Weighted average exercise price, outstanding (in dollars per share)		$ 1.69	$ 1.87	$ 1.41	$ 1.87
Share-based Payment Arrangement, Employee [Member]
Number of options (in shares)	1,953,443	1,953,443	1,212,442	1,212,442
Weighted average exercise price, outstanding (in dollars per share)	$ 1.88	$ 1.88	$ 1.71	$ 1.71
Weighted average remaining contractual life, outstanding (Year)		7 years	2 years 4 months 24 days	3 years 1 month 2 days	2 years 4 months 24 days
Aggregate intrinsic value, outstanding		$ 188,018	$ 0	$ 476,964	$ 0
Number of options granted (in shares)		2,032,175	0
Weighted average exercise price, granted (in dollars per share)		$ 2.48	$ 0
Number of options exercised (in shares)		(435,558)	0
Weighted average exercise price, exercised (in dollars per share)		$ 1.58	$ 0
Number of options forfeited and expired (in shares)		0
Weighted average exercise price, forfeited or expired (in dollars per share)		$ 0
Number of options exercisable (in shares)		745,092	1,117,829
Weighted average exercise price, exercisable (in dollars per share)		$ 1.93	$ 1.84
Weighted average remaining contractual life, exercisable (Year)		2 years 4 months 28 days	1 year 10 months 2 days
Aggregate intrinsic value, exercisable		$ 124,701	$ 0
Common stock issued to employee for stock options exercised (in shares)		435,558	0
Number of options (in shares)		3,550,060	1,212,442	1,953,443	1,212,442
Weighted average exercise price, outstanding (in dollars per share)		$ 2.26	$ 1.71	$ 1.88	$ 1.71

Note 9 - Stockholders' Equity_5

Note 9 - Stockholders' Equity - Schedule of Restricted Stock (Details) - Restricted Stock [Member] - $ / shares	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Non-vested, Shares (in shares)	0
Non-vested, Weighted Average Grant-Date Fair Value per Award (in dollars per share)	$ 2.52	$ 0
Granted, Shares (in shares)	79,365
Granted, Weighted Average Grant-Date Fair Value per Award (in dollars per share)	$ 2.52
Vested, Shares (in shares)	0
Vested, Weighted Average Grant-Date Fair Value per Award (in dollars per share)	$ 0
Non-vested, Shares (in shares)	79,365

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual)	6 Months Ended
	Jun. 30, 2021
Percentage of Valuation Allowance	100.00%

Note 11 - Segment and Geograp_3

Note 11 - Segment and Geographic Data (Details Textual)	6 Months Ended
	Jun. 30, 2021
Number of Reportable Segments	2

Note 11 - Segment and Geograp_4

Note 11 - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Product sales, net	$ 2,425,738	$ 167,674	$ 5,350,445	$ 1,979,060
Operating Income (Loss)	(2,872,572)	(3,172,890)	(3,856,945)	(4,781,496)
Depreciation and Amortization	14,834	21,138	35,760	54,457
Income (loss) before taxes and equity in earnings of affiliates	(2,600,853)	(3,176,952)	(3,587,761)	(4,789,655)
Total assets	21,059,666		21,059,666		$ 19,571,450
Corporate, Non-Segment [Member]
Operating Income (Loss)	(2,262,369)	(1,708,225)	(3,477,056)	(3,073,399)
Depreciation and Amortization	12,809	17,416	28,178	45,224
Income (loss) before taxes and equity in earnings of affiliates	(2,062,748)	(1,710,177)	(3,277,785)	(3,077,500)
Total assets	13,223,587		13,223,587		12,612,147
Dental Segment [Member]
Product sales, net	2,404,738	165,674	5,258,395	1,969,260
Dental Segment [Member] | Operating Segments [Member]
Product sales, net	2,404,738	165,674	5,258,395	1,969,260
Operating Income (Loss)	524,798	(650,236)	1,650,831	(223,856)
Depreciation and Amortization	860	3,101	2,566	8,800
Income (loss) before taxes and equity in earnings of affiliates	598,166	(651,384)	1,723,284	(225,845)
Total assets	6,639,102		6,639,102		6,035,645
Medical Segment [Member]
Product sales, net	21,000	2,000	92,050	9,800
Medical Segment [Member] | Operating Segments [Member]
Product sales, net	21,000	2,000	92,050	9,800
Operating Income (Loss)	(1,135,001)	(814,429)	(2,030,720)	(1,484,241)
Depreciation and Amortization	1,165	621	5,016	4,333
Income (loss) before taxes and equity in earnings of affiliates	(1,136,271)	$ (815,391)	(2,033,260)	$ (1,486,310)
Total assets	$ 1,196,977		$ 1,196,977		$ 923,658

Note 11 - Segment and Geograp_5

Note 11 - Segment and Geographic Data - Summary of Operations by Geographic Area (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Product sales, net	$ 2,425,738	$ 167,674	$ 5,350,445	$ 1,979,060
Dental Segment [Member]
Product sales, net	2,404,738	165,674	5,258,395	1,969,260
Medical Segment [Member]
Product sales, net	21,000	2,000	92,050	9,800
Domestic [Member]
Product sales, net	1,000,642	40,354	1,997,700	657,605
Domestic [Member] | Dental Segment [Member]
Product sales, net	1,000,642	38,354	1,989,550	655,605
Domestic [Member] | Medical Segment [Member]
Product sales, net	0	2,000	8,150	2,000
Domestic [Member] | Instruments [Member]
Product sales, net	178,752	0	354,768	525
Domestic [Member] | Instruments [Member] | Dental Segment [Member]
Product sales, net	178,752	0	354,768	525
Domestic [Member] | Instruments [Member] | Medical Segment [Member]
Product sales, net	0	0	0	0
Domestic [Member] | Handpieces [Member]
Product sales, net	802,916	38,812	1,606,050	635,490
Domestic [Member] | Handpieces [Member] | Dental Segment [Member]
Product sales, net	802,916	36,812	1,597,900	633,490
Domestic [Member] | Handpieces [Member] | Medical Segment [Member]
Product sales, net	0	2,000	8,150	2,000
Domestic [Member] | Accessories [Member]
Product sales, net	18,974	1,542	36,882	21,590
Domestic [Member] | Accessories [Member] | Dental Segment [Member]
Product sales, net	18,974	1,542	36,882	21,590
Domestic [Member] | Accessories [Member] | Medical Segment [Member]
Product sales, net
Rest of World [Member] | Instruments [Member]
Product sales, net	172,088	31,800	597,841	281,904
Rest of World [Member] | Instruments [Member] | Dental Segment [Member]
Product sales, net	156,588	31,800	539,841	274,304
Rest of World [Member] | Instruments [Member] | Medical Segment [Member]
Product sales, net	15,500	0	58,000	7,600
Rest of World [Member] | Handpieces [Member]
Product sales, net	715,124	87,632	1,689,459	1,018,123
Rest of World [Member] | Handpieces [Member] | Dental Segment [Member]
Product sales, net	709,624	87,632	1,663,559	1,017,923
Rest of World [Member] | Handpieces [Member] | Medical Segment [Member]
Product sales, net	5,500	0	25,900	200
Rest of World [Member] | Accessories [Member]
Product sales, net	12,548	7,888	33,109	21,428
Rest of World [Member] | Accessories [Member] | Dental Segment [Member]
Product sales, net	12,548	7,888	33,109	21,428
Rest of World [Member] | Accessories [Member] | Medical Segment [Member]
Product sales, net	0	0	0	0
International [Member]
Product sales, net	899,761	127,320	2,320,409	1,321,455
International [Member] | Dental Segment [Member]
Product sales, net	878,761	127,320	2,236,509	1,313,655
International [Member] | Medical Segment [Member]
Product sales, net	21,000	0	83,900	7,800
CHINA
Product sales, net	525,336	0	1,032,336	0
CHINA | Dental Segment [Member]
Product sales, net	525,336	0	1,032,336	0
CHINA | Medical Segment [Member]
Product sales, net	0	0	0	0
CHINA | Instruments [Member]
Product sales, net	78,000	0	228,000	0
CHINA | Instruments [Member] | Dental Segment [Member]
Product sales, net	78,000	0	228,000	0
CHINA | Instruments [Member] | Medical Segment [Member]
Product sales, net	0	0	0	0
CHINA | Handpieces [Member]
Product sales, net	447,336	0	804,336	0
CHINA | Handpieces [Member] | Dental Segment [Member]
Product sales, net	447,336	0	804,336	0
CHINA | Handpieces [Member] | Medical Segment [Member]
Product sales, net	0	0	0	0
CHINA | Other Products [Member]
Product sales, net	0	0	0	0
CHINA | Other Products [Member] | Dental Segment [Member]
Product sales, net				0
CHINA | Other Products [Member] | Medical Segment [Member]
Product sales, net	$ 0	$ 0	$ 0

Note 12 - Concentrations (Detai

Note 12 - Concentrations (Details Textual) - Customer Concentration Risk [Member]	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Revenue Benchmark [Member] | Domestic Distributor [Member]
Concentration Risk, Percentage	41.00%	24.00%	37.00%	33.00%
Revenue Benchmark [Member] | International Distributor [Member]
Concentration Risk, Percentage	57.00%	76.00%	63.00%	67.00%
Accounts Receivable [Member] | Domestic Distributor [Member]
Concentration Risk, Percentage			41.00%
Accounts Receivable [Member] | International Distributor [Member]
Concentration Risk, Percentage			59.00%
Accounts Receivable [Member] | Major Customer/distributor [Member]
Concentration Risk, Percentage					61.00%

Note 13 - Related Party Trans_2

Note 13 - Related Party Transactions (Details Textual) - USD ($)	Apr. 30, 2020	Apr. 29, 2020	Jan. 31, 2017	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Director [Member]
Deferred Compensation Arrangement with Individual, Compensation Expense						$ 0		$ 275,000
Consultant [Member]
Deferred Compensation Arrangement with Individual, Compensation Expense				$ 15,000		30,000
Director of Clinical Affairs [Member]
Royalty Expense				111,000	$ 97,000	248,000	$ 19,000
Professional Fees				39,000	39,000	78,000	78,000
Accounts Payable, Related Parties				134,000		134,000		127,000
Manufacturing Agreement for Handpieces [Member]
Related Party Transaction, Purchases from Related Party	$ 370,260	$ 370,260		384,000	751,000
Manufacturing Agreement for Handpieces [Member] | Accounts Payable, Related Parties, Current [Member]
Due to Related Parties, Current, Total				200,000		200,000		$ 362,000
Consulting Services [Member]
Related Party Transaction, Expenses from Transactions with Related Party				$ 25,000	25,000	$ 50,000	50,000
Consultant [Member] | Innovest S.p.A. [Member]
Related Party Transaction, Expenses from Transactions with Related Party					$ 20,000		$ 40,000
Consulting Services Agreement, Term (Year)			12 years

Note 14 - Commitments (Details

Note 14 - Commitments (Details Textual)	Jul. 10, 2017USD ($)	Jan. 01, 2005	Feb. 28, 2021	Aug. 31, 2019USD ($)	Jun. 30, 2015USD ($)ft²	Jun. 30, 2021USD ($)	Mar. 31, 2021USD ($)	Mar. 02, 2021	Mar. 01, 2021	Dec. 31, 2020USD ($)
Advances on Inventory Purchases						$ 1,393,817				$ 414,202
Operating Lease, Right-of-Use Asset							$ 593,049			597,770
Operating Lease, Liability, Total							594,416			630,012
Operating Lease, Liability, Current						76,008	76,008			72,031
Operating Lease, Liability, Noncurrent						518,408	518,408			557,981
Finance Lease, Liability, Total							32,595			36,403
Finance Lease, Liability, Current						8,162	8,162			7,796
Finance Lease, Liability, Noncurrent						$ 24,433	$ 24,433			$ 28,607
Additional Percentage of Director Compensation on Sales Value Using Certain Specify Technology		2.50%
Additional Percentage of Director Compensation Sales Value Using Other Kind of Technology		5.00%
Previous President and Chief Executive Officer [Member]
Increase (Decrease) in Deferred Compensation	$ (100,000)
Employment Agreement, Base Compensation	200,000
Consultant [Member]
Increase (Decrease) in Deferred Compensation	100,000
Employment Agreement, Base Compensation	$ 200,000
Interim Chief Executive Officer [Member]
Royalty on Net Sales, Percentage								2.50%
Director Clinical Affair [Member]
Royalty on Net Sales, Percentage								2.50%	5.00%
Office Lease for Headquarter in Livingston, New Jersey [Member]
Area of Rentable Space (Square Foot) | ft²					774
Operating Leases, Monthly Rent Expense					$ 12,522
Lessee, Operating Lease, Electric Charge Per Square Foot				$ 2
Lessee, Operating Lease, Electric Payments, Annually				11,130
Office Lease for Headquarter in Livingston, New Jersey [Member] | Minimum [Member]
Operating Leases, Monthly Rent Expense				9,275
Office Lease for Headquarter in Livingston, New Jersey [Member] | Maximum [Member]
Operating Leases, Monthly Rent Expense				$ 10,898
Purchase Commitment for Devices [Member]
Purchase Commitment Number Of Units						2,000
Purchase Commitment, Remaining Minimum Amount Committed						$ 2,900,000
Advances on Inventory Purchases						1,000,000
Purchase Commitment For Devices Beginning In 2021 [Member]
Purchase Commitment, Remaining Minimum Amount Committed						328,000
Advances on Inventory Purchases						150,000
Purchase Commitment For Epidural Disposable Kits Beginning In April 2021 [Member]
Purchase Commitment Number Of Units			1,185
Purchase Commitment, Remaining Minimum Amount Committed						197,000
Advances on Inventory Purchases						$ 172,000

Note 14 - Commitments - Lease E

Note 14 - Commitments - Lease Expense (Details) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Cash paid for operating lease liabilities		$ 31,303	$ 30,820	$ 62,606	$ 48,084
Cash paid for finance lease liabilities		2,685	2,685	5,370	4,937
Right-of-use assets obtained in exchange for new operating lease liabilities (1)	[1]	0	0	0	(663,009)
Property and equipment obtained in exchange for new finance lease liabilities		$ 0	$ 0	$ 0	$ (43,242)
Weighted-average remaining lease term - operating leases (years) (Year)		5 years 9 months 18 days	6 years 9 months 18 days	5 years 9 months 18 days	6 years 9 months 18 days
Weighted-average remaining lease term- finance leases (years) (Year)		3 years 7 months 6 days	4 years 7 months 6 days	3 years 7 months 6 days	4 years 7 months 6 days
[1]	For the six months ended June 30, 2021, the balance includes operating leases existing as of the adoption of ASC 842 on January 1, 2021

Note 15 - Subsequent Events (De

Note 15 - Subsequent Events (Details Textual)	May 24, 2021USD ($)
Chief Financial Officer [Member]
Base Annual Salary	$ 200,000